Company: IMNN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022120
Chunk: 4

Company: Imunon, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 4
---
 to the Company’s income tax disclosure.

In
November 2024, the FASB issued ASU No. 2024-03, “Income Statement – Reporting Comprehensive Income – Expense Disaggregation
Disclosures: Disaggregation of Income Statement Expenses” (“ASU 2024-03”). ASU 2024-03 will require more detailed information
about the types of expenses in commonly presented income statement captions such as “Cost of sales” and “Selling, general
and administrative expenses”. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and
interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact
that this change will have on the Company’s disclosures.

Note
4. Net Loss per Common Share

Basic
and diluted net loss per common share was computed by dividing net loss for the year by the weighted average number of shares of common
stock outstanding, both basic and diluted, during each period. The impact of common stock equivalents has been excluded from the computation
of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive.

The
total number of shares of common stock issuable upon exercise of warrants, stock option grants and equity awards was 990,233 and 447,499
shares for the nine months ended September 30, 2025 and 2024, respectively. For the nine-month periods ended September 30, 2025 and 2024,
diluted loss per common share was the same as basic loss per common share as the other warrants, and equity awards that were convertible
into shares of the Company’s common stock were excluded from the calculation of diluted loss per common share as their effect would
have been anti-dilutive.

The
Company declared a 15% stock dividend that was distributed on August 21, 2025 to stockholders of record as of August 7, 2025. In accordance
with Accounting Standards Codification (“ASC”) 260, basic and diluted earnings per share amounts and weighted-average shares outstanding have been restated for all periods
presented to reflect the effect of this stock dividend. The Company did not pay any dividends during the first nine months of 2024.

Note
5. Segment Performance Measures and Expenses

The
Company operates in one segment for the research and development of product candidates. The Company’s chief operating decision